The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1731
June 23, 2025
View Complete Issue         Table of Contents 2019 
Vutrisiran (Amvuttra) for Transthyretin Amyloid Cardiomyopathy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vutrisiran (Amvuttra) for Transthyretin Amyloid Cardiomyopathy
June 23, 2025 (Issue: 1731)
The FDA has approved vutrisiran (Amvuttra – Alnylam), a subcutaneously injected small interfering RNA (siRNA), to reduce cardiovascular hospitalizations, urgent heart failure visits, and cardiovascular death in adults with wild-type or variant...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vutrisiran (Amvuttra) for Transthyretin Amyloid Cardiomyopathy
Article code: 1731b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.